Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.6667.

A number of research firms have recently weighed in on ACRV. Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st. Finally, Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday.

Acrivon Therapeutics Stock Performance

Shares of ACRV opened at $1.77 on Friday. The stock has a fifty day moving average price of $1.69 and a two-hundred day moving average price of $1.94. Acrivon Therapeutics has a 52-week low of $1.05 and a 52-week high of $3.56. The company has a market cap of $75.76 million, a price-to-earnings ratio of -0.89 and a beta of 2.01.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). As a group, research analysts predict that Acrivon Therapeutics will post -1.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACRV. UBS Group AG grew its stake in Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after acquiring an additional 682,763 shares during the period. Marshall Wace LLP boosted its position in shares of Acrivon Therapeutics by 231.4% during the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after buying an additional 346,366 shares during the period. Jane Street Group LLC acquired a new position in shares of Acrivon Therapeutics during the second quarter worth about $371,000. Two Sigma Investments LP boosted its position in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Acrivon Therapeutics by 19.6% during the first quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock worth $1,054,000 after buying an additional 124,271 shares during the period. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.